Efficacy of levocarnitine as an add-on treatment to branched-chain amino acid-enriched nutritional supplementation on liver cirrhosis complicated by hepatic encephalopathy -a open-label study

Efficacy of levocarnitine as an add-on treatment to branched-chain amino acid-enriched nutritional supplementation on liver cirrhosis complicated by hepatic encephalopathy -a open-label study - Efficacy of levocarnitine for hepatic encephalopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012096

Enrollment

Registered

2013-10-28

Start date

2013-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Oral administration of levocarnitine No oral administration of levocarnitine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Past history of hepatic encephalopathy and latent hepatic encephalopathy 2) Hyperammonemia 3) Histologically proven or clinically diagnosed liver cirrhosis 4) Written informed consent 5) Patients should take levocarnitine for more than 3 months.

Exclusion criteria

Exclusion criteria: 1) No administration of other test drugs within 3 months 2) No administration of other branched-chain amino acid enriched supplements 3) Severe concurrent disease 4) Pregnant and lactating females 5) Contraindication for levocarnitine and branched-chain amino acid enriched supplements 6) Inappropriate for entry onto this study in the judgment of the investigator

Design outcomes

Primary

Measure	Time frame
Improvement of the symptoms caused by hyperammonemia	—

Countries

Japan

Contacts

Public ContactTomoyuki Nemoto

Faculty of Medical Sciences, University of Fukui Second Department of Internal Medicine

nemotot@u-fukui.ac.jp0776-61-8351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026